Key result
Paclitaxel-eluting stents show late thrombotic occlusion beyond one year, potentially influenced by metabolic control.
Why the study?
PCI is less effective in type 2 diabetic patients than in non-diabetic patients, and glycaemic and lipid control may impact clinical outcomes after elective PCI.
Highlights the potential risk of late thrombotic occlusion occurring more than one year after the implantation of a paclitaxel-eluting stent.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Chi‐Hang Lee (2004) studied this question. Paclitaxel-eluting stents can develop late thrombotic occlusion more than one year after implantation, which may be impacted by glycaemic and lipid control in diabetic patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: